For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.
He first came into contact with the stock market and shares during his banking apprenticeship. After completing this in 2000, he gained his first journalistic experience in the editorial department of a financial portal. During his subsequent studies in business administration, he also worked in the area of investor relations.
Since then, he has remained true to the capital markets and is excited to report on every newly discovered interesting story - as well as on long-standing success stories.
Commented by Fabian Lorenz
Commented by Fabian Lorenz on December 20th, 2023 | 07:15 CET
Shares for 2024: TUI in travel boom, Pfizer with monster dividend, Almonty Industries receives millions from Germany
Three shares from three different sectors and countries: TUI, Pfizer, and Almonty Industries. Are they among the top performers in 2024? At least there are good reasons for a turnaround in all of them. At TUI, the turnaround seems to have already begun. Will it continue? Almonty Industries is facing a decisive year. With the help of Germany's KfW, a massive tungsten mine in South Korea is set to go into operation in 2024. If this succeeds, turnover and profits will likely multiply in the coming years. Like so many Corona winners, Pfizer shares have suffered withdrawal symptoms this year. Will the pharmaceutical giant get back on track in 2024 after hitting a ten-year low? In any case, the dividend yield of 6% is attractive.
Read
Commented by Fabian Lorenz on December 19th, 2023 | 07:10 CET
Star investor Buffett bets on oil: BYD, Plug Power, Shell, Prospera Energy
While the world was watching the Dubai Climate Conference, Warren Buffett invested in oil. The star investor increased his stake in Occidental Petroleum to 27% via Berkshire Hathaway. There is also the possibility of increasing the stake in the US oil company to 33%. The move came after Occidental shares had lost 20% in just a few weeks. This anti-cyclical move is typical of Buffett and shows that oil stocks like Shell are exciting. A similar turnaround story to Occidental is Prospera Energy. Things are expected to get interesting for the Canadian oil producer next year. This is likely also the case for BYD and Plug Power. Chinese companies want to attack the Japanese market, among other things. Like so many hydrogen companies, Plug Power has to address the question of the profitability of its business model.
Read
Commented by Fabian Lorenz on December 14th, 2023 | 07:20 CET
Climate Conference and Nel disappoint. BASF and Saturn Oil + Gas shares recommended as Buy
The World Climate Conference has disappointed - at least for anyone who had hoped for a clear stance on the end of fossil fuels. Negotiations on the final declaration took place throughout the night in Dubai. The result is sobering. The farewell to fossil fuels is only vaguely described. It has become clear in recent weeks that fossil fuels are here to stay for the foreseeable future and that their lobby is strong. Instead of new impetus, shareholders of Nel ASA received further bad news. The hydrogen pioneer had to announce the cancellation of a major order. And that is not all. BASF, on the other hand, has a tailwind. The share has been upgraded from "Sell" to "Buy". Analysts see more than 200% upside potential for Saturn Oil & Gas. The high cash flow enables the oil producer to expand production and reduce debt.
Read
Commented by Fabian Lorenz on December 13th, 2023 | 07:30 CET
Several 100% upside potential? BioNTech, Bayer, Cardiol Therapeutics and Evotec in analyst check
We take a look at analysts' opinions on biotech and pharmaceutical stocks. Jefferies recently renewed its "Buy" recommendation for Evotec with a target price of EUR 34. The latest partnerships confirm that the Company's unique business model is working. The situation at Bayer is quite different. While the CEO is announcing radical changes, analysts are slashing their price targets, in some cases significantly. In contrast, analysts believe that Cardiol Therapeutics could achieve several 100% gains. The cash register is full to bursting, and an exciting news flow can be expected in 2024. At BioNTech, only the cash position is currently convincing. However, this is not enough for a buy recommendation.
Read
Commented by Fabian Lorenz on December 7th, 2023 | 08:40 CET
TUI strong! BYD reacts to share price slide! First Hydrogen share price about to jump?
TUI shares reacted to strong figures yesterday with a jump of over 10%. The tourism group also announced its intention to leave London and relocate its headquarters to Germany. However, the initial reactions from analysts were somewhat cautious. Given BYD's disappointing performance throughout the year, price reductions and negative analyst opinions have led to another sell-off. Now, the Company has decided to buy back its own shares, but will that be enough for an upward trend? First Hydrogen has several pieces of promising news. The Canadians have introduced their hydrogen fuel cell commercial vehicles in the UK, and interest is high. Furthermore, they plan to enter battery production with a partner. Will the three shares take off further, driven by the positive news?
Read
Commented by Fabian Lorenz on December 5th, 2023 | 06:40 CET
More than 30% with Plug Power, Siemens Energy, and Globex Mining! What is next?
Is the Plug Power share about to triple? Despite being one of the disappointments of 2023 along with Siemens Energy, both shares have risen in recent days. And analysts see further upside potential. The price target for the hydrogen specialist, in particular, is surprising. On the other hand, Globex Mining is performing well operationally throughout 2023. The shares of the mining incubator from North America have gained over 30% in value this year, outperforming commodity giants such as Barrick Gold. The Canadians' recent transaction shows that the business model has potential and is appealing to investors.
Read
Commented by Fabian Lorenz on November 30th, 2023 | 07:10 CET
Biotech Alert! Morphosys, Bayer, BioNTech and Defence Therapeutics
Morphosys is not for the faint-hearted. After unclear study results, the stock gave up its annual gains within a few days. Analysts are also divided on what the future holds. On December 10, the study details will be released, hopefully shedding light on the situation. Bayer shareholders are currently seeing dark clouds. The stock plummeted from EUR 40 to EUR 30 in a short time. Is the dividend now at risk, or is the entire company in jeopardy? There is a slew of positive news for Defence Therapeutics. Can the stock break out of its sideways trend? A potential partner for the Canadians could be BioNTech. The German biotech favourite is working with full coffers on cancer vaccines. However, analysts remain cautious.
Read
Commented by Fabian Lorenz on November 29th, 2023 | 10:00 CET
Sell Varta shares? Positive news from JinkoSolar and Manuka Resources
Is the Varta share price party over again? The shares of the former German battery darling have gained around 30% in value over the past six months. But now analysts are advising to sell. JinkoSolar's management had hoped for more buying when it announced the dividend at the end of September. While this was not the case, shareholders can at least look forward to a payout next week. Manuka Resources is currently managing the balancing act between positive cash flows from the sale of gold and investments in resource expansion. The Company is sitting on another potential "treasure" with a project for battery metals. Is the share undervalued?
Read
Commented by Fabian Lorenz on November 24th, 2023 | 13:00 CET
100% upside potential with hydrogen! Siemens Energy, thyssenkrupp and dynaCERT instead of Nel?
Is there about to be a changing of the guard in the hydrogen sector? There are significant doubts that the previous investor favorites, Nel and Plug Power, will get their losses under control. Who could be the new favorites? Siemens Energy and BASF are working on a production plant for CO2-free hydrogen. The partners are now receiving funding from the federal government and the state of Rhineland-Palatinate. dynaCERT is having its technology tested under the toughest conditions. The hydrogen and emissions reduction specialist is equipping a team for the Dakar Classic Rally. Could 2024 bring revenue growth? thyssenkrupp nucera shows that you can also earn money with hydrogen. Analysts see almost 100% share price potential.
Read
Commented by Fabian Lorenz on November 23rd, 2023 | 07:40 CET
Buy now? Morphosys, Siemens Energy and Desert Gold share
What do renewable energies, biotech and gold have in common? Shares from these sectors have predominantly experienced significant losses in 2023. Morphosys, Siemens Energy and Desert Gold are examples of this. However, the underperformers in the current year are often among the top performers in the upcoming year. Can this apply to these three shares? In the case of Morphosys, the latest study data has been confusing, and the share has given back its gains of the year. Analysts are now expressing their views. Siemens Energy has lost over 30% of its value due to operational problems, and the price targets of the experts vary widely. Explorer Desert Gold has been quiet recently. Is it the calm before a price jump? In any case, the share is anything but expensive.
Read